SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Type 1 Diabetes
Pipeline
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Press Releases
1/12/2026
Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial
1/9/2026
Diamyd Medical’s lead immunotherapy for type 1 diabetes receives global non-proprietary name retogatein
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research